Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2006 Mar;67(2):81–102. doi: 10.1016/j.curtheres.2006.04.001

Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study

Poobalan Naidoo 1,*, Rambiritch Virendra 1, Mayet Layla 2
PMCID: PMC3965989  PMID: 24678087

Abstract

Objectives: The aims of this study were to determine the effects of increasing doses of gliclazide on postprandial glucose excursions after a standardized breakfast and lunch, and to clarify the relationship between gliclazide dose and glucose response.

Methods: This prospective, open-label, case-controlled, dose-escalation study was conducted at the Addington Hospital Diabetes Clinic, eThekwini/Durban, KwaZulu-Natal, South Africa. Male and female patients aged ≥18 years with type 2 diabetes mellitus (DM) and postprandial hyperglycemia (2-hour postprandial blood glucose [PPBG2 h] level, ≥11.1 mmol/L [≥200 mg/dL]) and receiving an oral hypoglycemic agent were eligible. After a 1-week washout period during which patients were asked to discontinue treatment with all oral hypoglycemic agents, baseline glycemic measurements were performed (fasting blood glucose, PPBG2 h, 6-hour postprandial blood glucose [PPBG6 h], mean blood glucose [MBG], plasma insulin, fasting serum fructosamine, and glycosylated hemoglobin). All patients subsequently received 2 weeks of oral treatment with each of 3 doses of gliclazide: 40, 80, and 160 mg/d. Glycemic parameters were measured at the end of each dosing interval. Adverse-effect monitoring included direct reporting of untoward effects to the resident medical practitioner, clinical examination, monitoring of home blood glucose records, hematology, and liver and kidney function tests. Compliance was assessed using pill counts, examination of diary entries, and patient interview.

Results: Thirty-three patients were screened; 14 entered the dose-escalation phase. Thirteen patients completed the study (7 women, 6 men; mean [SD] age, 52.0 [11.1] years); 1 was withdrawn because of poor compliance. Dose escalation from 40 to 80 mg/d was associated with a significant change only in MBG (mean [SD], 11.3 [4.2] vs 10.0 [3.9] mmol/L [203.6 (75.7) vs 180.1 (70.3) mg/dL]; P<0.001). Dose escalation from 80 to 160 mg/d was associated with a significant change only in PPBG6 h (9.5 [4.2] vs 10.3 [4.1] mmol/L [171.1 (75.7) vs 185.6 (73.9) mg/dL]; P=0.018). No other significant changes in glycemic parameters between doses were found throughout the treatment period. No adverse effects were reported.

Conclusions: In this small study of gliclazide dose escalation in patients with type 2 DM and postprandial hyperglycemia, gliclazide 80 mg/d was associated with a reduction in postprandial hyperglycemia. Dose escalation from 80 to 160 mg/d was not found to be associated with additional clinical benefit. Based on these results, we recommend that gliclazide dose escalation to the maximum dose recommended by the manufacturer be guided by measures of glycemia. All doses were well tolerated.

Key words: type 2 diabetes mellitus, oral antidiabetic agents, oral hypoglycemic agents, gliclazide, postprandial hyperglycemia, sulfonylureas

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

References

  • 1.The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi: 10.1056/NEJM199309303291401. [DOI] [PubMed] [Google Scholar]
  • 2.UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713. [published correction appears in BMJ. 1999;318:29] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia. 2003;46(Suppl 1):M9–M16. doi: 10.1007/s00125-002-0931-5. [DOI] [PubMed] [Google Scholar]
  • 4.Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822–1826. doi: 10.2337/diacare.20.12.1822. [DOI] [PubMed] [Google Scholar]
  • 5.Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: The epidemiological evidence. Diabetologia. 2001;44:2107–2114. doi: 10.1007/s001250100020. [DOI] [PubMed] [Google Scholar]
  • 6.Manderson JG, Patterson CC, Hadden DR. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: A randomized controlled clinical trial. Am J Obstet Gynecol. 2003;189:507–512. doi: 10.1067/s0002-9378(03)00497-6. [DOI] [PubMed] [Google Scholar]
  • 7.de Veciana M, Major CA, Morgan MA. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 1995;333:1237–1241. doi: 10.1056/NEJM199511093331901. [DOI] [PubMed] [Google Scholar]
  • 8.Charbonnel BH, Matthews DR, Schernthaner G, QUARTET Study Group A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: A randomized, double-blind, parallel-group comparison trial. Diabet Med. 2005;22:399–405. doi: 10.1111/j.1464-5491.2004.01426.x. [DOI] [PubMed] [Google Scholar]
  • 9.Harrower A. Gliclazide modified release: From once daily administration to 24-hour glucose control. Metabolism. 2000;49(Suppl 2):7–11. doi: 10.1053/meta.2000.17823. [DOI] [PubMed] [Google Scholar]
  • 10.Palmer KJ, Brogden RN. Gliclazide: An update of its pharmacological properties and therapeutic efficacy in non-insulin dependent diabetes mellitus. Drugs. 1993;46:92–125. doi: 10.2165/00003495-199346010-00007. [DOI] [PubMed] [Google Scholar]
  • 11.Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: Brief overview. Diabetes. 2004;53(Suppl 3):S151–S155. doi: 10.2337/diabetes.53.suppl_3.s151. [DOI] [PubMed] [Google Scholar]
  • 12.Shaw KM, Wheeley MS, Campbell DB, Ward JD. Home blood glucose monitoring in non-insulin-dependent diabetics: The effect of gliclazide on blood glucose and weight control, a multicentre trial. Diabet Med. 1985;2:484–490. doi: 10.1111/j.1464-5491.1985.tb00688.x. [DOI] [PubMed] [Google Scholar]
  • 13.World Medical Association (WMA) Declaration of Helsinki . WMA; Ferney-Voltaire, France: 1989. (Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects). [WMA Web site] Accessed March 6, 2006. Accessed March 6, 2006. [Google Scholar]
  • 14.South Africa Dept. of Health The patients' rights charter. http://www.doh.gov.za/docs/legislation/patientsright/chartere.html Available at. Accessed March 7, 2006.
  • 15.Expert Committee on the Diagnosis and Classificaiion of Diabetes Mellitus. American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care. 2002;25(Suppl 1):S1–S147. doi: 10.2337/diacare.25.2007.s1. [DOI] [PubMed] [Google Scholar]
  • 16.Tulloch-Reid MK, Williams DE, Looker HC. Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians. Diabetes Care. 2003;26:2556–2561. doi: 10.2337/diacare.26.9.2556. [DOI] [PubMed] [Google Scholar]
  • 17.Buoen C, Holm S, Thomsen MS. Evaluation of the cohort size in phase I dose escalation trials based on laboratory data. J Clin Pharmacol. 2003;43:470–476. doi: 10.1177/0091270003252243. [DOI] [PubMed] [Google Scholar]
  • 18.World Health Organization (WHO) WHO; Geneva, Switzerland: 2000. Obesity: Preventing and Managing the Global Epidemic.http://www.whqlibdoc.who.int/trs/WHO_TRS_894.pdf (WHO Technical Report Series 804). Available at: Accessed March 7, 2006. [PubMed] [Google Scholar]
  • 19.Iverson C, Flanagin A, Fontanrosa PB, American Medical Association . 9th ed. Lippincott Williams & Wilkins; Philadelphia, Pa: 1998. pp. 486–503. (American Medical Assocaition Manual of Style: A Guide for Authors and Editors). [Google Scholar]
  • 20.Guillausseau PJ. An evaluation of long-term glycemic control in non-insulin-dependent diabetes mellitus: The relevance of glycated hemoglobin. Am J Med. 1991;90:46S–49S. doi: 10.1016/0002-9343(91)90417-v. (Suppl) [DOI] [PubMed] [Google Scholar]
  • 21.Kilo C, Dudley J, Kalb B. Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract. 1991;14(Suppl 2):S79–S82. doi: 10.1016/0168-8227(91)90012-3. [DOI] [PubMed] [Google Scholar]
  • 22.Scott RS, Donnelly T. No effect of gliclazide on gastric inhibitory polypeptide (GIP) in type II diabetes. Diabetes Res Clin Pract. 1987;3:175–178. doi: 10.1016/s0168-8227(87)80024-4. [DOI] [PubMed] [Google Scholar]
  • 23.Sinay IR, Arias P, Schnitman MA. Diet only or diet and sulfonylureas in mild type II diabetes (NIDDM)? Pathophysiologic and therapeutic implications. Acta Diabetol Lat. 1988;25:289–297. doi: 10.1007/BF02581127. [DOI] [PubMed] [Google Scholar]
  • 24.Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabetes Metab. 1991;17:209–212. [PubMed] [Google Scholar]
  • 25.Brogard JM, Pinget M, Dorner M. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics. Curr Med Res Opin. 1984;9:56–63. doi: 10.1185/03007998409109560. [DOI] [PubMed] [Google Scholar]
  • 26.Wing JR, Panz VR, Joffe BI, Seltel HC. Changes in glucose disposal and cellular insulin binding in obese black Southern African patients with type 2 diabetes mellitus before and after sulphonylurea therapy. Diabet Med. 1993;10:50–55. doi: 10.1111/j.1464-5491.1993.tb01996.x. [DOI] [PubMed] [Google Scholar]
  • 27.DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 1992;15:318–368. doi: 10.2337/diacare.15.3.318. [DOI] [PubMed] [Google Scholar]
  • 28.DeFronzo RA, Gunnarsson R, Bjorkman O. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 1985;76:149–155. doi: 10.1172/JCI111938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. [published correction appears in Lancet. 1999;354:602] [PubMed] [Google Scholar]
  • 30.UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352:854–865. [published correction appears in Lancet. 1998;352:1558] [PubMed] [Google Scholar]
  • 31.DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303. doi: 10.7326/0003-4819-131-4-199908170-00008. [DOI] [PubMed] [Google Scholar]
  • 32.Ceriello A, Johns D, Widel M. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care. 2005;28:266–272. doi: 10.2337/diacare.28.2.266. [published correction appears in Diabetes Care. 2005; 28:1272] [DOI] [PubMed] [Google Scholar]
  • 33.Rambiritch V. University of KwaZulu-Natal; KwaZulu-Natal, South Africa: 2004. Pharmacokinetics and pharmacodynamics of glibenclamide in type 2 diabetics. (dissertation). [Google Scholar]
  • 34.Jonsson A, Hallengren B, Rydberg T, Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab. 2001;3:403–409. doi: 10.1046/j.1463-1326.2001.00152.x. [DOI] [PubMed] [Google Scholar]
  • 35.Krentz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs. 2005;65:385–411. doi: 10.2165/00003495-200565030-00005. [DOI] [PubMed] [Google Scholar]
  • 36.Wahlin-Boll E, Sartor G, Melander A, Schersten B. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol. 1982;22:21–25. doi: 10.1007/BF00606420. [DOI] [PubMed] [Google Scholar]
  • 37.Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med. 1993;118:169–172. doi: 10.7326/0003-4819-118-3-199302010-00002. [DOI] [PubMed] [Google Scholar]
  • 38.Jackson L, Robertson L. Sulphonylureas (specifically glibenclamide) and their correct dosage. S Afr Med J. 1989;76:286. [PubMed] [Google Scholar]
  • 39.Heerdink ER, Urquhart J, Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf. 2002;11:447–453. doi: 10.1002/pds.745. [DOI] [PubMed] [Google Scholar]
  • 40.Rambiritch V, Naidoo P. Gliclazide modified release. Drugs. 2005;65:1449–1450. doi: 10.2165/00003495-200565100-00009. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES